CONTACT US
PIONEERING THE USE OF THE ELANE PATHWAY TO CREATE THE NEXT-GENERATION OF PAN-CANCER THERAPEUTICS
Location
9880 Campus Point Drive, Suite 420 San Diego, California 92121LATEST NEWS
Keep up to date with all the latest news from Onchilles Pharma
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Subscribe To Our Newsletter
Keep up to date with all the latest news from Onchilles Pharma